Ann: iPPS Increases Cartilage Thickness in Phase 2 Trial, page-148

Or build your position.

Capital cost/raising fears aside, PAR has progressed its trial/commercialisation pathways in five years. For those with the cash or new to PAR, this indisputably presents an opportune levels to go long PAR versus past levels across the same timeline:


@Dungiven form previous posts and comments from PAR, appears to feel it would easier for them to change dosing than yourself (sorry, tagging you, because you appear far more informed than most on the dosing discussion):



Other similar commentary suggests the lower dosage was at behest of the FDA from animal studies, when SAS use always suggested 2mg/kg the better option and the FDA left the door open for PAR to raise in its phase III trial.